Remicade Biosimilar Market is set to Grow at a Remarkable Pace by 2032
During the forecast period, the remicade biosimilar market is expected to develop at a CAGR of 35.9%. In 2022, the market is currently valued at US$ 2212.86 million. The market value of the remicade biosimilar market is expected to reach US$ 47,549.77 million by 2032. Biosimilars are biological products that are highly similar to an already FDA-approved medicine, known as the reference biological product. Biosimilars are medications that have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) and have no clinically significant changes from the reference products in terms of safety, purity, efficacy, and effectiveness. These biosimilar medications can only be approved for indications and conditions that have previously been approved by major regulatory agencies for the reference product. Remicade (infliximab) is a monoclonal antibody that was developed in collaboration between Janssen Biotech Inc. and Merck & Co. (MSD) and was a...